Supplementary Table 1 Systematic literature review search terms

Set #	Searched for	Results
S1	EMB.EXACT.EXPLODE("Behcet disease") OR MESH.EXACT.EXPLODE("Behcet Syndrome") OR TI,AB("Behcet" OR "Behcets" OR "Behcet's" OR "Behçet" OR "Behçets" OR "Behçet's" OR "silk road disease" OR "silkroad disease" OR Adamantiades)	28,050
S2	TI,AB((randomi?ed controlled trial) OR RCT OR placebo* OR “randomly allocated” OR (allocated NEAR/2 random*) OR (clinical NEAR/1 trial*) OR ((singl* OR doubl* OR treb* or tripl*) NEAR/1 (blind[*3] OR mask[*3]))) OR EMB.EXACT("clinical trial" OR "randomized controlled trial" OR "controlled clinical trial" OR "multicenter study" OR "phase 1 clinical trial" OR "phase 2 clinical trial" OR "phase 3 clinical trial" OR "phase 4 clinical trial" OR "single blind procedure" OR "double blind procedure" OR "crossover procedure" OR "placebo" OR "prospective study") OR EMB.EXACT.EXPLODE(randomization) OR MESH.EXACT(“Randomized Controlled Trials as Topic” OR “Randomized Controlled Trial” OR “Random Allocation” OR “Double Blind Method” OR “Single Blind Method” OR “Clinical Trial” OR Placebos) OR MESH.EXACT.EXPLODE(“Clinical Trials as Topic”)	3,626,419
S3	TI,AB(oral OR mouth OR periodontal OR gums OR gingiva OR stomatitis OR aphthous OR canker OR mucocutaneous) OR EMB.EXACT("aphthous stomatitis") OR MESH.EXACT("Stomatitis, Aphthous")	1,642,713
S4	S1 AND S2 AND S3	404
S5	S4 NOT dtype("Conference Abstract")	310

Supplementary Table 2 Study design and patient demographics of included randomized controlled trials

Citation	Country	Study duration	Treatment arms	N	Mean (SD) age, years	Males, %
Aktulga 1980[1]	Turkey	6 months	Colchicine	14	34.2 (7.2)	64.3
			Placebo	14	33 (12.8)	92.9
Davatchi 2009[2]	Iran	8 months[a]	Colchicine	136	31.2 (8.29)	32.3
			Placebo	146		
Yurdakul 2001[3]	Turkey	24 months	Colchicine	58	Females: 26.7 (4.8) Males: 27 (5.5)	51.7
			Placebo	58	Females: 27.2 (5.2) Males: 27.3 (5.3)	51.7
Calguneri 1996[4]	Turkey	16 months	Colchicine	60	36.1 (10.0)	50
			Colchicine + benzathine penicillin	95	37.4 (9.4)	53.2
Hatemi 2015[5]	Turkey, United States	24 weeks[b]	Apremilast	55	34.3	29
			Placebo	56	34.7	32
Hatemi 2019[6]	Multi-country	64 weeks[c]	Apremilast	104	39.4	38.5
			Placebo	103	40.6	38.8
Alpsoy 2002[7]	Turkey	12 weeks	Interferon α-2a	23	32.82 (8.17)	69.6
			Placebo	21	31.89 (7.85)	52.4
Hamuryudan 1991[8]	Turkey	24 weeks	Interferon α-2c hydrogel	30	NR	41.3
			Placebo	31	NR	
Kilic 2009[9]	Turkey	12 weeks	Interferon-α lozenges (1000 IU)	31	37	35.5
			Interferon-α lozenges (2000 IU)	26	36	26.9
			Placebo	27	36	25.9
Hamuryudan 1998[10]	Turkey	24 weeks	Thalidomide (100 mg/day)	31	27.6	100
			Thalidomide (300 mg/day)	32	27.8	100
			Placebo	32	26.7	100
Fani 2012[11]	Iran	1 week	Triamcinolone acetonide	30	35.47 (8.85)	26.7
			Phenytoin syrup	30	38.77 (9.4)	26.7
Masuda 1989[12]	Japan	16 weeks[d]	Cyclosporine	47	NR	NR
			Colchicine	49	NR	NR
Melikoğlu 2005[13]	Turkey	4 weeks	Etanercept	20	28.5 (5.3)	100
			Placebo	20	30.8 (6.2)	100
Yazici 1990[14]	Turkey	24 months	Azathioprine	37	Group 1: 31.8 (4.3) Group 2: 32.1 (5.3)	100
			Placebo	36	Group 1: 30.5 (5.2) Group 2: 31.5 (6.5)	100

Notes: [a] Crossover trial; patients received 4 months of treatment, followed by crossover and an additional 4 months of treatment.
[b] Trial included a 12-week, placebo-controlled, active treatment phase, followed by a 12-week apremilast-exposure period.
[c] Trial included a 12-week, placebo-controlled active treatment phase, followed by a 52-week apremilast-exposure period.
[d] Patients had the option to continue cyclosporine in a long-term open study.
Abbreviations: IU, international unit; NR, not reported.

References

1. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behçet's disease. *Haematologica*. 1980;65(3):399-402.
2. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. *Mod Rheumatol*. 2009;19(5):542-549.
3. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behçet's syndrome. *Arthritis Rheum*. 2001;44(11):2686-2692.
4. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. *Dermatology.* 1996;192(2):125-128.
5. Hatemi G, Melikoğlu M, Tunc R, Korkmaz C, Ozturk BT, Mat C, et al. Apremilast for Behçet's syndrome - a phase 2, placebo-controlled study. *N Engl J Med.* 2015;372(16):1510-1518.
6. Hatemi G, Mahr A, Ishigatsubo Y, Song YW, Takeno M, Kim D, et al. Trial of apremilast for oral ulcers in Behçet's syndrome. *N Engl J Med*. 2019;381(20):1918-1928.
7. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. *Arch Dermatol.* 2002;138(4):467-471.
8. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet's syndrome: a randomized, double blind trial. *Br J Rheumatol.* 1991;30(5):395-396.
9. Kiliç H, Zeytin HE, Korkmaz C, Mat C, Gül A, Coşan F, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome. *Rheumatology.* 2009;48(11):1388-1391.
10. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1998;128(6):443-450.
11. Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behçet's syndrome. *Iran Red Crescent Med J.* 2012;14(2):75-78.
12. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. *Lancet.* 1989;1(8647):1093-1096.
13. Melikoğlu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. *J Rheumatol.* 2005;32(1):98-105.
14. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet's syndrome. *N Engl J Med.* 1990;322(5):281-285.